박혜인 교수
1577-5587
전문진료분야
급·만성 신장기능 저하의 진단 및 치료, 유전성 신질환의 진단 및 유전상담, 신장조직검사를 통한 사구체신염의 진단, 투석치료
전화 예약
1577-5587
기본정보
학력
1998.03 ~ 2005.02한림대학교 의학 졸업 2008.09 ~ 2010.08한림대학교 대학원 의학석사 졸업 2011.03 ~ 2013.02서울대학교 대학원 의학박사 졸업 |
경력
2005 ~ 2010서울대학교병원 수련의 2010 ~ 2013서울대학교병원 내과 임상강사 2011 ~ 2012서울대학교병원 장기이식센터 임상강사 2013 ~ 2014서울대학교병원 연구조교수 2014 ~ 2018국군수도병원 신장내과 분과장 2018 ~ 2020한림대학교강남성심병원 신장내과 임상조교수 2020 ~ 한림대학교강남성심병원 신장내과 부교수 |
학회활동
대한내과학회 정회원 대한신장학회 정회원 대한신장학회 대외협력위원 대한신장학회 COVID-19 TFT 위원 국제신장학회 정회원 |
수상이력
2005한림대학교의과대학 총장상(성적우수) 2017국제군진외상학술대회 최우수 포스터상 |
논문
◎ 국내학회지 발표논문
1. Fighting coronavirus disease-2019 (COVID-19): The role of a COVID-19 Task Force Team. Kidney Res Clin Pract 2021; Online ahead of print.
2. Who is the winner, pre- post-, or mixed-dilution hemodiafiltration? Kidney Res Clin Pract 2021; Online ahead of print.
3. Urinary angiotensinogen in addition to imaging classification in the prediction of renal outcome in autosomal dominant polycystic kidney disease. J Korean Med Sci 2020;35(22):e165.
4. Korean clinical practice guidelines for preventing transmission of coronavirus disease 2019 (COVID-19) in hemodialysis facilities. Kidney Res Clin Pract 2020;39(2):145-150.
5. Korean clinical practice guidelines for preventing the transmission of infections in hemodialysis facilities. Kidney Res Clin Pract 2018; 37(1): 8-19.
6. Xp11.2 translocation renal cell carcinoma in autosomal dominant polycystic kidney patient with preserved renal function. Korean J Intern Med 2017; 32(6): 1108-1111.
7. Middle East respiratory syndrome clinical practice guideline for hemodialysis facilities. Kidney Res Clin Pract 2017; 36(2): 111-116.
8. Recent advances in the management of autosomal dominant polycystic kidney disease. Korean J Med 2015; 89(2): 169-178.
9. Recurrent thrombotic events after catastrophic antiphospholipid syndrome. Korean J Intern Med 2012; 27(2): 232-234.
10. Lower residual renal function is a risk factor for depression and impaired health-related quality of life in Korean peritoneal dialysis patients. J Korean Med Sci 2012; 27(1): 64-71.
11. Transcatheter arterial embolization therapy for a massive polycystic liver in autosomal dominant polycystic kidney disease patients. J Korean Med Sci 2009; 24(1): 57-61.
◎ 국제학회지 발표논문
1. Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study. PLoS One 2021;16(6):e0252186.
2. Age-adjusted Charlson comorbidity index score is the best predictor for severe clinical outcome in the hospitalized patients with COVID-19 infection. Medicine 2021;100(18):e25900.
3. Clinical outcomes of initially asymptomatic patients with COVID-19: a Korean nationwide cohort study. Ann Med 2021;53(1):357-364.
4. Health insurance status is related to risk of mortality and hospitalization in Korean maintenance hemodialysis patients: A longitudinal cohort study. Am J Nephrol 2020;51(12):975-981.
5. Genetic identification of inherited cystic kidney diseases for implementing precision medicine: a study protocol for a 3-year prospective multicenter cohort study. BMC Nephrol 2021;22(1):2.
6 Effect of isolation practice on the transmission of middle east respiratory syndrome coronavirus among hemodialysis patients: A 2-year prospective cohort study. Medicine 2020;99(3):e18782.
7. Genetic characteristics of Korean patients with Autosomal dominant polycystic kidney disease by targeted exome sequencing. Sci Rep 2019:9(1):16952.
8. Diabetic retinopathy is a prognostic factor for progression of chronic kidney disease in the patients with type 2 diabetes mellitus. PLoS One 2019;14(7):e0220506.
9. Diagnostic evaluation as a biomarker in patients with ADPKD. Adv Exp Med Biol 2016; 933:85-103.
10. Increased urinary angiotensinogen/creatinine ratio may be associated with reduced renal function in ADPKD. BMC Nephrol 2015; 16:86.
11. Identification of novel PKD1 and PKD2 mutations in Korean patients with autosomal dominant polycystic kidney disease. BMC Med Genet 2014;15:129.
12. Chronic asymptomatic pyuria precedes overt urinary tract infection and deterioration of renal function in autosomal dominant polycystic kidney disease. BMC Nephrol 2013; 14:1.
13. Urinary N-acetyl-beta-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study. BMC Nephrol 2012; 13:93.
14. Depression and health-related quality of life in maintenance hemodialysis patients. Clin Nephrol 2010; 73(5): 374-380.
1. Fighting coronavirus disease-2019 (COVID-19): The role of a COVID-19 Task Force Team. Kidney Res Clin Pract 2021; Online ahead of print.
2. Who is the winner, pre- post-, or mixed-dilution hemodiafiltration? Kidney Res Clin Pract 2021; Online ahead of print.
3. Urinary angiotensinogen in addition to imaging classification in the prediction of renal outcome in autosomal dominant polycystic kidney disease. J Korean Med Sci 2020;35(22):e165.
4. Korean clinical practice guidelines for preventing transmission of coronavirus disease 2019 (COVID-19) in hemodialysis facilities. Kidney Res Clin Pract 2020;39(2):145-150.
5. Korean clinical practice guidelines for preventing the transmission of infections in hemodialysis facilities. Kidney Res Clin Pract 2018; 37(1): 8-19.
6. Xp11.2 translocation renal cell carcinoma in autosomal dominant polycystic kidney patient with preserved renal function. Korean J Intern Med 2017; 32(6): 1108-1111.
7. Middle East respiratory syndrome clinical practice guideline for hemodialysis facilities. Kidney Res Clin Pract 2017; 36(2): 111-116.
8. Recent advances in the management of autosomal dominant polycystic kidney disease. Korean J Med 2015; 89(2): 169-178.
9. Recurrent thrombotic events after catastrophic antiphospholipid syndrome. Korean J Intern Med 2012; 27(2): 232-234.
10. Lower residual renal function is a risk factor for depression and impaired health-related quality of life in Korean peritoneal dialysis patients. J Korean Med Sci 2012; 27(1): 64-71.
11. Transcatheter arterial embolization therapy for a massive polycystic liver in autosomal dominant polycystic kidney disease patients. J Korean Med Sci 2009; 24(1): 57-61.
◎ 국제학회지 발표논문
1. Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study. PLoS One 2021;16(6):e0252186.
2. Age-adjusted Charlson comorbidity index score is the best predictor for severe clinical outcome in the hospitalized patients with COVID-19 infection. Medicine 2021;100(18):e25900.
3. Clinical outcomes of initially asymptomatic patients with COVID-19: a Korean nationwide cohort study. Ann Med 2021;53(1):357-364.
4. Health insurance status is related to risk of mortality and hospitalization in Korean maintenance hemodialysis patients: A longitudinal cohort study. Am J Nephrol 2020;51(12):975-981.
5. Genetic identification of inherited cystic kidney diseases for implementing precision medicine: a study protocol for a 3-year prospective multicenter cohort study. BMC Nephrol 2021;22(1):2.
6 Effect of isolation practice on the transmission of middle east respiratory syndrome coronavirus among hemodialysis patients: A 2-year prospective cohort study. Medicine 2020;99(3):e18782.
7. Genetic characteristics of Korean patients with Autosomal dominant polycystic kidney disease by targeted exome sequencing. Sci Rep 2019:9(1):16952.
8. Diabetic retinopathy is a prognostic factor for progression of chronic kidney disease in the patients with type 2 diabetes mellitus. PLoS One 2019;14(7):e0220506.
9. Diagnostic evaluation as a biomarker in patients with ADPKD. Adv Exp Med Biol 2016; 933:85-103.
10. Increased urinary angiotensinogen/creatinine ratio may be associated with reduced renal function in ADPKD. BMC Nephrol 2015; 16:86.
11. Identification of novel PKD1 and PKD2 mutations in Korean patients with autosomal dominant polycystic kidney disease. BMC Med Genet 2014;15:129.
12. Chronic asymptomatic pyuria precedes overt urinary tract infection and deterioration of renal function in autosomal dominant polycystic kidney disease. BMC Nephrol 2013; 14:1.
13. Urinary N-acetyl-beta-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study. BMC Nephrol 2012; 13:93.
14. Depression and health-related quality of life in maintenance hemodialysis patients. Clin Nephrol 2010; 73(5): 374-380.